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Abstract 
Electron paramagnetic resonance (EPR) spectroscopy, coupled with site-directed spin labeling 
(SDSL), is a useful method for studying conformational changes of biomolecules in cells. In 
order to employ in-cell EPR using nitroxide-based spin labels, the structure of the nitroxides 
must confer reduction resistance in order to withstand the reductive environment within cells. 
Here we report the synthesis of two new spin labels, EÇ and EÇm, both of which possess the 
rigidity and the reduction resistance needed for extracting detailed structural information by 
EPR spectroscopy. EÇ and EÇm were incorporated into DNA and RNA, respectively, by 
oligonucleotide synthesis. Both labels were shown to be non-perturbing of duplex structure. 
Partial reduction of EÇm during RNA synthesis was circumvented by protection of the nitroxide 




Nucleic acids are central to molecular biology and partake in essential biological processes,1  
including storage, expression and transmission of genetic information,2 as well as catalysis of 
chemical reactions3, 4 and regulation of genetic expression.5-7 Understanding their biological 
functions relies on structural knowledge. Biomolecules have been intensively studied in vitro 
by a number of biochemical and biophysical methods, such as X-ray crystallography,8 nuclear 
magnetic resonance (NMR) spectroscopy,9, 10 Förster resonance energy transfer (FRET)11, 12 
and electron paramagnetic resonance (EPR) spectroscopy.13-16 Although biomolecules have 
been extensively studied in vitro, the question remains whether the structure and dynamics of 
biomolecules are different in cells, since the intracellular environment may be impossible to 
reproduce in vitro, in particular factors such as viscosity, molecular crowding, interactions with 
other macromolecules, and concentration of ions.17  
Increased effort is being directed towards exploring biomolecules within cells, in particular 
using spectroscopic methods, such as NMR, FRET and EPR.17-20 In-cell NMR has been used 
to study the structure and dynamics of nucleic acids in several cell types, along with 
membranes and disordered proteins.17, 19-23 In-cell NMR has mostly been used to monitor 
enzymatic or “nonspecific” interactions,21 and requires isotopic labeling of molecules to 
overcome cellular background signals. In-cell FRET has been used to study inter- and intra-
molecular interactions through distance measurements between two fluorescent tags.24, 25 EPR 
spectroscopy has also been used to measure distances within biomolecules in cells and recent 
studies have highlighted its advantages.18, 26, 27 EPR requires small amounts of material, has 
virtually no background signals, is not limited by molecular size, and structural information can 
be readily obtained through distance measurements by dipolar EPR-experiments, such as 
pulsed electron-electron double resonance (PELDOR/DEER).26, 28-30  
There are examples of paramagnetic biomolecules, such as metalloproteins31 and proteins 
that contain paramagnetic cofactors.32 However, the majority of biomolecules are diamagnetic 
and, therefore, a paramagnetic center (spin label) must be introduced in order to carry out EPR 
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studies. For in-cell EPR, three types of spin labels have been used. Gd(III) complexes have 
been used for distance measurements in proteins (Figure 1A),33-35 for example ubiquitin that 
contained two 4PS-PyMTA-Gd(III) labels. Trityl radicals (Figure 1B) have also been used for 
distance measurements in cells, specifically between a trityl-labeled cytochrome P450 and a 
native metal cofactor.36 Nitroxides have also been used for in-cell EPR,18, 26, 28-30, 37-39 but 
limitation of most nitroxides is that they are rapidly reduced in the reducing environment 
encountered within cells.37, 40, 41 However, sterically-shielded nitroxides, in particular tetraethyl-
derived nitroxides, are resistant towards reduction.41 For example, a tetraethyl-derived 
pyrrolidine nitroxide has been used to spin label a chaperone protein for in-cell EPR (Figure 
1C). Only minimal reduction of the radical was observed and enabled the EPR study of 
structural features of the chaperone protein through determination of inter-spin distances.42 A 
tetraethyl-derived isoindoline spin label has recently been used for post-synthetic labeling of 
2’-amino groups of RNA (Figure 1D) and shown to be stable in the presence of ascorbic acid.43 
Preliminary in-cell EPR measurements with this label have revealed structural changes in 
duplex RNAs (unpublished data). However, the semi-flexible nature of the linker attaching the 





Figure 1. Different spin labels used for in-cell EPR measurements. A. 4PS-PyMTA-Gd(III) 
linked to a protein.44 B. A trityl-based spin label linked to a protein.36 C. M-TETPO linked to a 
protein.42 D. A tetra-ethyl derived spin label conjugated to a 2’-amino labeled uridine through 
a thiourea linkage.43 
The rigid spin labels Ç45 and Çm46 (Figure 2) have been shown to provide more detailed 
information on structural changes and dynamics in nucleic acids47 than flexible and semi-
flexible labels. Here we describe the synthesis and characterization of the corresponding 
tetraethyl nitroxide spin labels EÇ and EÇm (Figure 2). These spin labels combine two 
characteristics necessary for obtaining detailed structural information about nucleic acids in 





Figure 2. The rigid spin labels Ç45 and Çm46 and their corresponding tetraethyl derivatives EÇ 
and EÇm. 
Results and discussion 
Synthesis of EÇ and EÇm and their stability towards reduction 
The synthesis of EÇ and EÇm started with the preparation of ethylisoindoline derivative 4 
(Scheme 1). Compound 148 was aminated49 to afford amino-nitro derivative 2. Hydrolysis of 2 
yielded 3 and hydrogenation of the nitro group gave ethylisoindoline-derived aminophenol 4. 
To incorporate the ethylisoindoline moiety into nucleosides, the dihalogenated nucleosides 545 
and 646 were coupled with 4 in the presence of Et3N to provide intermediates 7 and 8, 
respectively, followed by ring-closure45, 46, 50 to afford phenoxazine derivatives EÇf and EÇmf. 
Direct oxidation of EÇf and EÇmf using either hydrogen peroxide and Na2WO445 or m-
chloroperoxybenzoic acid (m-CPBA)51 under a variety of conditions resulted in very low yields 
of the desired product along with multiple other products. However, oxidation of TBDMS-
protected EÇf and EÇfm with m-CPBA in the presence of NaN349 afforded 9 and 10 in excellent 
yields. The TBDMS groups were subsequently removed with TBAF to yield nucleosides EÇ 




Scheme 1. Synthesis of tetraethylisoindoline 4. 
The resistance of EÇm towards reduction in presence of ascorbic acid, frequently used to 
evaluate the stability of nitroxides,41 was investigated and compared to its tetramethyl 
derivative Çm.46 The normalized EPR signal intensity was plotted as a function of time and 
showed that the tetramethyl derived Çm was almost fully reduced within 1 h, while ca. 90% of 
the EÇm nucleoside was still intact after 16 h (Figure S29). 
The 5’-hydroxyl groups of EÇ and EÇm were protected as 4,4’-dimethoxytrityl (DMT) ethers 
and subsequent 3’-phosphitylation yielded phosphoramidites 11 and 12 (Scheme 2), used for 
incorporation of EÇ and EÇm into DNA and RNA oligonucleotides by solid phase synthesis, 
respectively. While working with DMT-protected EÇ, EÇm and phosphoramidites 11 and 12, 
we discovered that the DMT groups were unusually labile.  Even dissolving these compounds 
in polar and/or protic solvents, such as CH3CN or MeOH, lead to rapid loss of the DMT group. 
The use of nonpolar or chlorinated solvents such as CH2Cl2 or 1,2-dichloroethane 




Scheme 2. Synthesis of spin-labeled nucleosides EÇ and EÇm and their corresponding 
phosphoramidites. Yields were as follows: EÇf (56%, over 2 steps), EÇmf (60%, over 2 steps), 
9 (83% over 2 steps), 10 (81%, over 2 steps), EÇ (91%), EÇm (94%), 11 (77%, over 2 steps) 
and 12 (63%, over 2 steps). 
Syntheses of spin-labeled DNA oligonucleotides 
Phosphoramidite 11 was used for the synthesis of seven different oligodeoxynucleotides 
containing EÇ by automated solid-phase synthesis (Table S1). The DNAs varied in length and 
position of the spin-label. The spin-labeled phosphoramidite 11 coupled well during the solid-
phase synthesis, as indicated by a strong orange color of the trityl cation that appears during 
removal of the DMT group. Analysis of the crude oligodeoxynucleotides by denaturing 
polyacrylamide gel electrophoresis (DPAGE) did not reveal any failure bands that would have 
resulted for partial coupling of 11. The EÇ-modified oligomers migrated slightly slower than the 
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unmodified strands of the same sequence by DPAGE, consistent with incorporation of the spin 
label, which was confirmed by mass spectrometry (Table S1).  
The DNA oligomers were enzymatically digested and the digests were analyzed by high 
performance liquid chromatography (HPLC) (Figure S30).52, 53 The HPLC chromatograms for 
digests of DNAs I-VII each showed five peaks, one for each natural nucleoside and a strongly 
retained nucleoside that was shown by co-injection45 to be EÇ. Chromatograms for the longer 
oligonucleotides (III, IV, VI and VII) also contained an additional small peak around 20.5 
minutes that was shown by co-injection to be EÇf. It is well known that nitroxide radicals get 
partially,53 or even fully,54 reduced during oligonucleotide synthesis using the phosphoramidite 
approach. Although the tetraethyl groups on EÇ render the nitroxide significantly more 
resistant to reduction by common reducing agents, they do not provide full protection against 
reduction (through disproportionation)55 by the acids used for oligonucleotide synthesis, 
dichloroacetic acid and ethylthiotetrazole. The amounts of EÇf and EÇ was quantified, showing 
that ca. 6-18% of the spin-labels had been reduced. These results were further confirmed with 
spin-counting of DNAs I-VII by EPR spectroscopy giving 81-100% spin labeling (Table S1). It 
should be noted that more extensive reduction was observed in oligodeoxynucleotides of 
similar length that were synthesized using the phosphoramidite of the tetramethyl derived Ç.53  
A molecular model of a EÇ within a B-form DNA duplex (Figure 3A) shows that the spin label 
is well accommodated in the major groove of the duplex. To determine experimentally whether 
the EÇ spin-label caused a structural perturbation of the B-DNA, circular dichroism (CD) 
spectra were recorded (Figure S32), along with collecting thermal denaturation data (Table 1, 
Figure S33). The CD spectra of the modified and unmodified DNA duplexes were almost 
identical, all possessing negative and positive molar ellipticities at ca. 250 and 280 nm, 
respectively, characteristic of a right-handed B-DNA. In general, the thermal denaturation 
experiments showed that the spin labels did not result in a significant decrease in the melting 
temperature, with ΔTMs ranging from -0.8 to -2.8 °C. Increased stability was actually observed 
for duplexes B and I. The increase of the TM for duplex B of +5.6 °C and decrease for duplex 
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D of -1.5 °C, is nearly identical to what has been observed for Ç in the same location of the 













Table 1.  Sequences of spin-labeled DNA and 
RNA duplexes and their thermal denaturation 
analysis. 
 DNA and RNA sequences TM (°C) ΔTM 











F  63.8 -2.8 
G  65.0 -1.6 
H  65.8 -0.8 




K  74.0 -3.0 
L  76.0 -1.1 
M  75.6 -1.4 




Figure 3. Space-filling models of EÇ- and EÇm-labeled oligonucleotide duplexes. A. B-form 
DNA duplex with EÇ projected into the major groove. B. A-form RNA duplex containing EÇm. 
The oligonucleotide constituents are shown in grey and the spin-labeled nucleotides in red. 
All oligonucleotides were characterized by continuous-wave (CW) EPR spectroscopy (Figure 
S34), which also confirmed duplex formation. Figure 4 shows a comparison of the CW-EPR 
spectra of EÇ, the EÇ-labeled 19-mer DNA single strand III and the corresponding 19-mer 
DNA duplex F. The nucleoside showed three sharp lines (Figure 4A) that broadened after 
incorporation into the 19-mer oligoribonucleotide 5’-d(AGTGGAEÇGCTTGGGGTGTA)-3’ 
(Figure 4B). Upon annealing to its complementary strand 5’-
d(ATACAEÇCCCAAGCGTCCAC)-3’, the CW-EPR spectrum broadened further, showing a 
splitting of the high- and low-field components (Figure 4C), characteristic for the formation of 




Figure 4. A. EPR spectum of EÇ. B. EPR spectrum of a EÇ-labeled 19-mer DNA single strand 
5’-d(AGTGGAEÇGCTTGGGGTGTA)-3’. C. EPR spectrum of a EÇ-labeled duplex 5’-
d(AGTGGAEÇGCTTGGGGTGTA)-3’·5’-d(ATACAEÇCCCAAGCGTCCAC)-3’. EPR spectra 
were recorded at 20 °C in a phosphate buffer (2 nmol of DNA; 10 mM phosphate, 100 mM 
NaCl, 0.1 mM Na2EDTA, pH 7.0). 
Syntheses of spin-labeled RNA oligonucleotides 
In a manner analogous to the synthesis of EÇ-modified DNA, phosphoramidite 12 was used 
to synthesize five 21-nucleotide long EÇm-labeled RNAs (Table S1). HPLC chromatograms 
of enzymatic digests of RNAs XII-XVI (Figure S31A-E) showed five peaks, one for each 
natural nucleoside and one for EÇm. An additional peak or two were observed in digests of 
five oligonucleotides, one corresponding to inosine (from partial enzymatic hydrolysis of A by 
an adenosine deaminase-contamination in phosphodiesterase I)56 (Figure S31B, C, D and E) 
and the other corresponding to EÇmf (Figure S31A, B and D). The reduction of EÇm to EÇmf 
was determined from the chromatograms to be 30-49% and further confirmed by spin-counting 
using EPR spectroscopy (Table S1, XII, XIII and XV). The more extensive reduction of EÇm 
compared to reduction of EÇ during DNA synthesis can be explained by longer exposure of 
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the spin label to oligonucleotide reagents during RNA synthesis. Recent reports of protecting 
nitroxides prior to the oligonucleotide synthesis of RNA have shown to be effective to 
circumvent their reduction;53, 57 we chose to employ benzoyl protection of the corresponding 
hydroxylamine of EÇm.53  
Synthesis of Bz-EÇm and its corresponding phosphoramidite 
The synthesis of Bz-EÇm (Scheme 3) began with reduction of the TBDMS-protected nitroxide 
10 to yield the corresponding hydroxylamine, which was subsequently benzoylated to give 13. 
Heating 10 at 60 °C for 24 h with 20 equivalents of ascorbic acid was required for reducing this 
structurally hindered nitroxide. Subsequent removal of the TBDMS groups of 13 gave Bz-EÇm. 
The benzoyl protecting-group was shown to be stable under all conditions used for 
oligonucleotide synthesis for more than a week (data not shown) and was efficiently removed 
in 2.5 h using conventional deprotecting conditions for RNA (1:1, 40% MeNH2:40% NH3 in 
H2O), returning EÇm in quantitative yields. The 5’-hydroxyl group of Bz-EÇm (Scheme 3) was 
protected as 4,4’-dimethoxytrityl (DMT) ether and subsequently phosphitylated to give 




Scheme 3. Synthesis of Bz-EÇm and its corresponding phosphoramidite. 
Syntheses of spin-labeled RNA oligonucleotides using phosphoramidite 14 
Phosphoramidite 14 was used to repeat the synthesis of oligonucleotides XII, XIII and XV 
(Table S1). As before, the protected spin label coupled well during the solid-phase synthesis. 
Spin counting by EPR spectroscopy showed 96-99% spin labeling, indicating that little or no 
reduction of the spin label had occurred during the synthesis (Table S1, XVII, XVIII and XIX). 
This was further confirmed by HPLC analysis of the enzymatic digests of RNAs XVII, XVIII and 
XIX (Figure S31F, G and H), that showed complete absence of EÇmf. The HPLC analyses 
also showed that the benzoyl protecting group had been completely removed during the RNA 
deprotection. The stabilities of the spin-labeled duplexes V, XIV and the Ç-labeled DNA 5′-
PHO-d(TGAGGTAGTAGGTTGTATAÇT-3′ were tested in the presence of ascorbic acid, like 
before with the nucleosides. Figure. 5 shows the EPR signal as a function of time. There was 
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a striking difference in the stability of the tetraethyl derived spin-labeled oligonucleotides as 
compared to spin labels: the Ç-labeled DNA was fully reduced within 20 min while the tetraethyl 
labeled DNA(EÇ) and RNA(EÇm) were almost completely intact after 12 h 
 
Figure 5. Stabilities of EÇ-labeled DNA single strand V (square), EÇm-labeled RNA single-
strand XIV (triangle) and the Ç-labeled DNA 5′-PHO-d(TGAGGTAGTAGGTTGTATAÇT-3′ 
(circle) towards reduction (5 mM ascorbic acid, 10 mM phosphate, 100 mM NaCl, 0.1 mM 
Na2EDTA, pH 7.0), PHO is a phosphate. 
A model of EÇm within an A-form RNA duplex (Figure 3B) shows that the spin label fits tightly 
into the major groove of the duplex. CD spectra of the RNA duplexes (unmodified and modified) 
showed negative and positive molar ellipticities at ca. 210 nm and 263 nm, respectively, as 
expected for A-form RNA (Figure S32). Thermal denaturing experiments showed only minor 
destabilization of the duplexes by EÇm, with the ΔTMs ranging from -1.1 to -3.0 °C. Since each 
duplex contains two labels, the change in Tm caused by EÇm was less than -2.0 °C per 
modification, relative to the unmodified RNA, which is a similar result to that obtained with Çm 
modified RNA duplexes of similar length.46 All these RNA duplexes have one strand in common 
(Table S1, XVII) which is complimentary to all the other strands (Table S1, XVIII, XIV, XIX and 
XVI). Thus, the only difference between the spin-labeled duplexes is the position of EÇm in 
the complementary strand. Therefore, the minor differences in the melting temperatures are 
likely due to flanking-sequence dependence, as has been observed with both phenoxazine-




The tetraethyl-derived rigid spin labels EÇ and EÇm were synthesized and incorporated into 
DNA and RNA, respectively. The spin-labeled oligonucleotides were analyzed by UV-vis, CD 
and EPR spectroscopy as well as enzymatic digestion followed by HPLC analysis. Together 
this data verified incorporation of the spin labels and showed them to be non-perturbating of 
duplex structures. A minor reduction of the EÇ spin label was observed during the automated 
synthesis of EÇ-labeled DNA, but substantial reduction of EÇm took place during the synthesis 
of EÇm-labeled RNA. This reduction was circumvented by using a benzoyl protecting group 
for the hydroxylamine prepared from EÇm.53 The new tetraethyl-derived rigid labels EÇ and 
EÇm showed dramatically increased resistance towards reduction by ascorbic acid, when 
compared to its tetramethyl derivatives Ç45 and Çm,46 which will enable the investigation of 





General materials, instruments and methods. All commercially available reagents were 
purchased from Sigma-Aldrich co GMBH. or Acros Organics and used without further 
purification, except diisopropylammonium tetrazolide and 2-cyanoethyl N,N,N’,N’- 
tetraisopropylphosphorodiamidite, which were purchased from ChemGenes Corp., USA. All 
commercial phosphoramidites, CPG columns and solutions for oligonucleotide syntheses were 
also purchased from ChemGenes Corp., USA. 2’-Deoxyuridine and 2’-O-methyluridine were 
purchased from Rasayan Inc. USA. CH2Cl2, pyridine and CH3CN were dried over calcium 
hydride and freshly distilled before use. All moisture- and air-sensitive reactions were carried 
out in oven-dried glassware under an inert atmosphere of Ar. Thin-layer chromatography (TLC) 
was performed using glass plates pre-coated with silica gel (0.25 mm, F-25, Silicycle) and 
compounds were visualized under UV light and by p-anisaldehyde staining. Column 
chromatography was performed using 230–400 mesh silica gel (Silicycle). 1H-, 13C- and 31P-
NMR spectra were recorded with a Bruker Avance 400 MHz spectrometer. Commercial grade 
CDCl3 was passed over basic alumina shortly before dissolving tritylated nucleosides for NMR 
analysis. Chemical shifts are reported in parts per million (ppm) relative to the partially 
deuterated NMR solvents CDCl3 (7.26 ppm for 1H NMR and 77.16 ppm for 13C), CD3OD (3.35, 
4.78 ppm for 1H NMR and 49.3 ppm for 13C), and DMSO-d6 (2.49 ppm for 1H NMR and 39.7 
ppm for 13C). 31P-NMR chemical shifts are reported relative to 85% H3PO4 (at 0.0 ppm) as an 
external standard. All coupling constants are reported in Hertz (Hz). Nitroxide radicals show 
broadening and loss of NMR signals due to their paramagnetic nature and, therefore, those 
NMR spectra are not shown. Mass spectrometric analyses of all organic compounds were 
performed on an ESI-HRMS (Bruker, MicrOTOF-Q) in positive ion mode. DNA and RNA solid-
phase oligonucleotide syntheses were performed on an automated ASM800 DNA/RNA 
synthesizer (BIOSSET Ltd., Russia) using phosphoramidite chemistry. Unmodified and spin-
labeled oligonucleotides were synthesized using a trityl-off protocol and phosphoramidites with 
standard protecting groups on 1 μmol scale (1000 Å CPG columns). Oxidation was performed 
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with tert-butylhydroperoxide (1.0 M) in toluene. Capping and detritylation were performed using 
standard conditions for DNA and RNA synthesis. Concentrations of the oligonucleotides were 
determined by measuring UV absorbance at 260 nm using a Perkin Elmer Inc. Lambda 25 
UV/Vis spectrometer and calculated by Beer′s law. Mass spectrometric analyses of EÇ- and 
EÇm-labeled oligonucleotides were performed on an ESI-HRMS (Bruker, MicrOTOF-Q) in 
negative ion mode. HPLC analysis of enzymatic digests were performed on a Beckman Coulter 
Gold HPLC system using Beckman Coulter Ultrasphere C18 4.6 x 250 mm analytical column 
with UV detection at 254 nm. Solvent gradients for analytical RP-HPLC were run at 1.0 mL/min 
using the following gradient program: solvent A, TEAA buffer (50 mM, pH 7.0); solvent B, 
CH3CN; 0-4 min isocratic 4% B, 4-14 min linear gradient 4-20% B, 14-24 min linear gradient 
20-50% B, 24-29 min linear gradient 50-80% B, 29-30 min isocratic 80%, 30-35 min linear 
gradient 80-4% B and 35-45 min isocratic 4% B. CD spectra of the duplexes were recorded in 
a Jasco J-810 spectropolarimeter. Cuvettes with 1 mm path length were used and the CD data 
were recorded from 350 nm to 200 nm at 25 °C. Prior to analysis by CD, thermal denaturation 
and EPR, an appropriate quantity of each DNA or RNA stock solutions was dried on a Thermo 
Scientific ISS 110 SpeedVac and dissolved in phosphate buffer (10 mM phosphate, 100 mM 
NaCl, 0.1 mM Na2EDTA, pH 7.0). DNA and RNA duplexes were formed by annealing in an MJ 
Research PTC 200 Thermal Cycler using the following protocol: 90 °C for 2 min, 60 °C for 5 
min, 50 °C for 5 min, 40 °C for 5 min and 22 °C for 15 min. CW-EPR spectra were recorded 
on a MiniScope MS200 spectrometer using 100 kHz modulation frequency, 1.0 G modulation 
amplitude, and 2.0 mW microwave power. The samples were placed in a quartz capillary 
(BLAUBRAND intraMARK) prior to EPR measurements. 
1,1,3,3-Tetraethyl-6-nitroisoindolin-5-amine (2). To a solution of N,N,N-trimethylhydrazine 
iodide (1.83 g, 99.9 mmol) in DMSO (15 mL) was added t-BuOK (1.12 g, 99.9 mmol) and the 
solution stirred at 22 °C for 30 min. Compound 1 (1.00 g, 45.4 mmol) was added and the 
solution stirred further for 14 h. The reaction mixture was poured into ice-cold water (50 mL), 
followed by extraction with CH2Cl2 (3 x 50 mL), the combined organic phases dried over 
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Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash-column 
chromatography using a gradient elution (100:0 to 90:10, CH2Cl2:MeOH), to give compound 2 
(0.750 g, 70%) as an orange solid. 1H NMR (400 MHz, d6-DMSO) δ = 7.62 (s, 1H), 7.29 (s, 
2H), 6.73 (s, 1H), 1.56 (qdd, J = 13.8, 7.3, 4.2 Hz, 8H), 0.80 (q, J = 7.6 Hz, 12H) ppm. 13C{1H} 
NMR (101 MHz, d6-DMSO) δ = 157.0, 146.0, 136.2, 130.0, 118.1, 111.5, 67.3, 66.5, 40.1, 39.9, 
39.7, 39.5, 39.3, 39.0, 38.8, 33.3, 33.0, 8.8, 8.7, 8.6 ppm. HRMS (ESI-TOF) m/z: [M + H]+ 
Calcd for C16H26N3O2+: 292.2020; found 292.2017. 
1,1,3,3-Tetraethyl-6-nitroisoindolin-5-ol (3). To a solution of potassium hydroxide (13.1 g, 
0.234 mmol) in 10% H2O/MeOH (80 mL) was added 1,1,3,3-tetraethyl-6-nitroisoindolin-5-
amine (2) (2.75 g, 11.7 mmol) and the reaction mixture heated in a closed vial at 140 ºC for 24 
h. The reaction mixture was poured onto ice and extracted with EtOAc (3 x 100 mL), the 
combined organic phases were dried over Na2SO4 and the solvent was removed in vacuo. The 
residue was purified by flash-column chromatography, using a gradient elution (100:0 to 90:10, 
CH2Cl2:MeOH), to give compound 3 (2.01 g, 72%) as a bright yellow solid. 1H NMR (400 MHz, 
CDCl3) δ = 10.69 (s, 1H), 7.77 (s, 1H), 6.82 (s, 1H), 1.76 – 1.59 (m, 8H), 0.89 (t, J = 7.5 Hz, 
12H) ppm. 13C{1H} NMR (101 MHz, CDCl3) δ = 155.1, 133.0, 118.5, 113.1, 33.62, 33.43, 29.7, 
8.78, 8.73 ppm. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C16H25N2O3+: 293.1860; found 
293.1878. 
6-Amino-1,1,3,3-tetraethylisoindolin-5-ol (4). A solution of compound 3 (400 mg, 2.54 mmol) 
in MeOH (30 mL) containing 10% Pd/C (40.0 mg) was stirred in the dark under an atmosphere 
of H2 (1 atm) for 2 h. The reaction mixture was filtered through a pad of celite and the filtrate 
was concentrated in vacuo to yield crude product 4 (348 mg), which was directly used for the 
next step without further purification. 1H NMR (400 MHz, CDCl3) δ =6.48 (s, 2H), 1.83 – 1.49 
(m, 8H), 1.07 – 0.59 (m, 12H). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C16H27N2O+: 263.2118; 
found 263.2111. 
((2R,3S,5R)-3-acetoxy-5-(5-bromo-4-chloro-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-
yl)methyl acetate (5). A solution of 5-Bromo-3',5'-diacetyl-2'-deoxyuridine (0.80 g, 2.05 mmol) 
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and PPh3 (1.34 g, 5.13mmol), in a mixture of CH2Cl2 and CCl4 (10 + 10 mL), was refluxed for 
40 min. The solvent was removed in vacuo, and the residue was purified by silica gel flash 
column chromatography using a gradient elution (EtOAc/CH2Cl2; 5:95 to 15:85) to yield 
compound 5 as a white solid (0.63 g, 75% yield). 1H NMR (400 MHz, CDCl3) δ = 8.20 (s, 1H), 
6.04 (t, J = 6.4 Hz, 1H), 5.12 (dt, J = 6.3, 2.9 Hz, 1H), 4.38 – 4.20 (m, 3H), 2.73 (ddd, J = 14.5, 
6.0, 3.0 Hz, 1H), 2.14 (dt, J = 14.3, 6.7 Hz, 1H), 2.03 (s, 3H), 2.00 (s, 3H).13C{1H} NMR (101 
MHz, CDCl3) δ 170.2, 170.0, 165.5, 151.4, 144.0, 100.0, 97.1, 88.1, 83.5, 77.6, 77.3, 76.9, 
73.4, 63.2, 60.3, 53.6, 38.9, 21.0, 20.8, 14.1. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C13H14BrClN2O3Na+ 430.9616; Found 430.9628. 
5-Bromo-3',5'-diacetyl-N-4-(2-hydroxytetraethylisoindolinyl)-2'-deoxycytidine (7). To a 
solution of compound 4 (262 mg, 0.706 mmol) and compound 5 (346 mg, 0.847 mmol) in CHCl3 
(10 mL) was added Et3N (180 µL, 1.29 mmol) and the solution stirred at 22 °C for 16 h. The 
solvent was removed in vacuo, and the crude product was used in the next reaction without 
purification. 1H NMR (400 MHz, CDCl3) δ = 7.97 (s, 1H), 7.84 (s, 1H), 7.39 (s, 1H), 6.80 (s, 
1H), 6.31 – 6.20 (m, 1H), 5.21 (dt, J = 5.9, 2.5 Hz, 1H), 4.38 (d, J = 3.3 Hz, 2H), 4.32 (d, J = 
3.0 Hz, 1H), 2.71 (ddd, J = 14.2, 5.6, 2.4 Hz, 1H), 2.15 (s, 3H), 2.10 (s, 3H), 1.85 – 1.67 (m, 
8H), 0.87 (q, J = 7.4 Hz, 13H). 13C{1H} NMR (101 MHz, CDCl3) δ = 170.4, 170.2, 157.0, 153.4, 
148.7, 140.4, 125.5, 116.1, 88.6, 86.9, 82.9, 77.2, 73.9, 63.7, 50.8, 39.0, 32.9, 32.7, 31.9, 29.7, 
29.4, 22.7, 20.9, 20.9, 14.1, 8.8, 8.7 ppm. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C29H40BrN4O7+: 635.2075; found 635.2063. 
7,7,9,9-tetraethyl-3-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-
7,8,9,11-tetrahydropyrimido[4',5':5,6][1,4]oxazino[2,3-f]isoindol-2(3H)-one (EÇf). To a 
solution of compound 7 (449 mg, 0.706 mmol) in abs. EtOH (50 mL) was added KF (1.0 g, 
17.0 mmol) and the mixture was refluxed for 42 h. The reaction mixture was cooled to room 
temperature and the salts were filtered from the solution. The filtrate was concentrated in vacuo 
and the residue purified by flash-column chromatography, using a gradient elution (100:0 to 
75:25, CH2Cl2:MeOH),  to yield EÇf (187 mg, 56%) as a pale yellow solid. 1H NMR (400 MHz, 
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CD3OD) δ = 7.67 (s, 1H), 6.67 (s, 1H), 6.44 (s, 1H), 6.21 (t, J = 6.5 Hz, 1H), 4.37 (dt, J = 6.6, 
3.7 Hz, 1H), 3.91 (q, J = 3.0 Hz, 1H), 3.86 – 3.65 (m, 2H), 2.31 (ddd, J = 13.3, 5.8, 3.6 Hz, 1H), 
2.13 (dt, J = 13.4, 6.6 Hz, 1H), 1.61 (qd, J = 14.0, 11.6, 7.3 Hz, 8H), 0.81 (dd, J = 8.8, 4.8 Hz, 
12H) ppm. 13C{1H} NMR (101 MHz, CD3OD) δ = 156.4, 155.9, 144.2, 143.5, 143.3, 129.9, 
127.0, 123.5, 112.0, 110.8, 89.1, 87.6, 72.2, 70.2, 70.1, 62.8, 42.0, 34.4, 34.3, 9.4, 9.3 ppm. 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C25H35N4O5+: 471.2602; found 471.2603. 
3-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-
butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-7,7,9,9-tetraethyl-7,8,9,11-
tetrahydropyrimido[4',5':5,6][1,4]oxazino[2,3-f]isoindol-2(3H)-one (TBDMS-EÇf). A 
solution of EÇf (2.30 g, 4.89 mmol), TBDMSCl (2.21 g, 14.7 mmol) and imidazole (0.992 g, 
14.7 mmol) in a mixture of pyridine and DMF (1:1, 20 mL) was stirred at 22 °C for 24 h. The 
reaction mixture was poured onto ice and extracted with EtOAc (3 x 100 mL), the combined 
organic phases were dried over Na2SO4 and the solvent removed was in vacuo. The residue 
was purified by flash-column chromatography, using a gradient elution (100:0 to 90:10, 
CH2Cl2:MeOH), to yield TBDMS-EÇf (3.38 g, 99%) as a pale yellow solid. 1H NMR (400 MHz, 
CDCl3) δ = 7.45 (s, 2H), 6.33 (s, 1H), 6.25 (t, J = 6.1 Hz, 1H), 4.42 – 4.35 (m, 1H), 3.96 – 3.83 
(m, 2H), 3.83 – 3.71 (m, 1H), 2.33 (ddd, J = 13.2, 6.2, 4.3 Hz, 1H), 2.08 – 1.95 (m, 2H), 1.67 
(s, 8H), 0.96 (s, 9H), 0.89 (s, 21H), 0.15 (d, J = 8.4 Hz, 6H), 0.09 – 0.04 (m, 9H) ppm. 13C{1H} 
NMR (101 MHz, CDCl3) δ = 154.7, 153.8, 128.1, 108.9, 87.7, 85.9, 77.4, 71.4, 62.7, 41.9, 33.7, 
29.8, 26.2, 26.0, 25.9, 22.8, 18.6, 18.1, 8.9, 1.2, -4.5, -4.7, -5.3, -5.3 ppm. HRMS (ESI-TOF) 
m/z: [M + H]+ Calcd for C37H63N4O5Si2+: 699.4332; found 699.4280. 
3-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-
butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-7,7,9,9-tetraethyl-8-oxyl-7,8,9,11-
tetrahydropyrimido[4',5':5,6][1,4]oxazino[2,3-f]isoindol-2(3H)-one (9). To a solution of 
TBDMS-EÇf (400 mg, 0.572 mmol) in CH2Cl2 (10 mL) was added NaN3 (198 mg, 1.14 mmol) 
and the solution stirred for 15 min at 22 °C. m-CPBA (74.9 mg, 1.14 mmol) was added and the 
solution stirred for 4 h. The reaction mixture was concentrated in vacuo and the crude product 
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purified by flash-column chromatography, using a gradient elution (100:0 to 83:17, 
CH2Cl2:MeOH), to yield 9 (339 mg, 83%) as a bright yellow solid. HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C37H61N4O6Si2Na•+: 736.4022; found 736.3997. 
7,7,9,9-tetraethyl-8-oxidanyl-3-((2R,4S,5R)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-7,8,9,11-
tetrahydropyrimido[4',5':5,6][1,4]oxazino[2,3-f]isoindol-2(3H)-one (EÇ). To a solution of 9 
(500 mg, 0.700 mmol) in anhydrous THF (3 mL) was added TBAF (2.03 mL, 7.00 mmol) and 
the solution stirred at 22 °C for 12 h. The solvent was removed in vacuo and the residue purified 
by flash-column chromatography, using a gradient elution (100:0 to 75:25, CH2Cl2:MeOH), to 
yield EÇ (310 mg, 91%) as a yellow solid. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C25H33N4O6Na•+: 508.2298; found 508.2292 
3-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-
hydroxytetrahydrofuran-2-yl)-7,7,9,9-tetraethyl-8-oxidanyl-7,8,9,11-
tetrahydropyrimido[4',5':5,6][1,4]oxazino[2,3-f]isoindol-2(3H)-one (DMT-EÇ). Residual 
MeOH was co-evaporated with toluene (3 x 5 mL) from EÇ (477 mg, 0.982 mmol), followed by 
sequential addition of pyridine (10 mL), DMTrCl (433 mg, 1.28 mmol) and DMAP (27.0 mg, 
0.197 mmol). The solution was stirred at 22°C for 6 h, MeOH (400 μL) was added and the 
solvent removed in vacuo. The residue was purified by flash-column chromatography, using a 
gradient elution (1:99:0 to 1:95.5:3.5, Et3N:CH2Cl2:MeOH), to yield DMT- EÇ (735 mg, 95%) 




yl)tetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite (11). To a solution of 
DMT- EÇ (100 mg, 0.127 mmol) in CH2Cl2 (5 mL) were added diisopropylammonium 
tetrazolide (171 mg, 1.52 mmol) and 2-cyanoethyl N,N,N’,N’-tetraisopropylphosphorodiamidite 
(52 µL, 0.17 mmol). The resulting solution was stirred at 22 °C for 2 h. CH2Cl2 (50 mL) was 
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added and the organic phase washed sequentially with satd. aq. NaHCO3 (3 × 50 mL) and 
brine (50 mL), dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in a 
minimum amount of CH2Cl2 (few drops), followed by a slow addition of n-hexane (40-50 mL) 
at 22 °C. The solvent was decanted from the precipitate and discarded. This procedure was 
repeated four times to give 11 (100 mg, 80%) as a yellowish solid. 31P NMR (162 MHz, CDCl3): 
δ = 150.27, 149.35 ppm. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C55H68N6O9Na•+: 
1010.4678; found 1010.4578,  
5-Bromo-3',5'-diacetyl-N-4-(2-hydroxytetraethylisoindolinyl)-2'-methoxycytidine (8). To 
a solution of compound 4 (592 mg, 2.03 mmol) and 6 (1021 mg, 2.32 mmol) in CHCl3 (10 mL) 
was added Et3N (180 µL, 1.29 mmol) and the solution stirred at 22 °C for 16 h. The solvent 
was removed in vacuo, and the crude product was used in the next reaction without 
purification. 1H NMR (400 MHz, CDCl3) δ = 8.30 (s, 1H), 7.98 (s, 1H), 7.82 (s, 1H), 7.57 (s, 
1H), 6.91 (s, 1H), 5.90 – 5.79 (m, 1H), 4.73 (dd, J = 9.3, 5.0 Hz, 1H), 4.47 – 4.29 (m, 3H), 4.05 
– 3.97 (m, 1H), 3.51 (s, 1H), 2.17 (s, 3H), 2.14 (s, 3H), 1.80 – 1.50 (m, 8H), 0.84 (dtd, J = 10.3, 
7.4, 3.8 Hz, 12H).13C{1H} NMR (101 MHz, CDCl3) δ = 170.2, 170.1, 170.04, 169.97, 166.0, 
157.6, 153.5, 153.1, 146.1, 145.6, 143.9, 142.5, 140.3, 127.5, 119.1, 116.3, 100.0, 89.8, 89.5, 
88.4, 87.5, 81.7, 81.7, 78.8, 78.4, 77.5, 77.4, 77.2, 76.9, 68.9, 68.7, 68.6, 68.4, 61.4, 61.1, 
59.0, 58.9, 53.5, 33.7, 33.5, 29.6, 21.09, 21.07, 20.51, 20.49, 8.9. HRMS (ESI-TOF) m/z: [M + 
H]+ Calcd for C30H42BrN4O8+: 665.2181; found 665.2165. 
7,7,9,9-tetraethyl-3-((2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-
methoxytetrahydrofuran-2-yl)-7,8,9,11-tetrahydropyrimido[4',5':5,6][1,4]oxazino[2,3-
f]isoindol-2(3H)-one (EÇmf). To a solution of compound 8 (1.35 g, 2.03 mmol) in abs. EtOH 
(200 mL) was added KF (1.18 g, 20.2 mmol) and the mixture was refluxed for 42 h. The mixture 
was cooled to room temperature and the salts were removed by filtration. The filtrate was 
concentrated in vacuo and the residue purified by flash-column chromatography, using a 
gradient elution (100:0 to 75:25, CH2Cl2:MeOH), to yield EÇmf (567 mg, 60%) as a pale yellow 
solid. 1H NMR (400 MHz, CD3OD) δ = 7.91 (s, 1H), 6.82 – 6.74 (m, 1H), 6.72 (s, 1H), 5.88 (d, 
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J = 2.6 Hz, 1H), 4.23 (dd, J = 7.1, 5.1 Hz, 1H), 4.02 – 3.87 (m, 2H), 3.85 – 3.73 (m, 2H), 3.57 
(s, 3H), 2.02 – 1.96 (m, 8H), 1.00 (td, J = 7.3, 4.7 Hz, 12H) ppm. 13C{1H} NMR (101 MHz, 
CD3OD) δ 156.1, 155.7, 144.9, 138.7, 138.0, 129.6, 129.3, 123.9, 112.4, 111.6, 89.7, 85.6, 
85.5, 75.4, 69.4, 61.2, 59.0, 49.7, 49.6, 49.5, 49.4, 49.3, 49.2, 49.1, 48.9, 48.7, 48.5, 48.0, 





EÇmf). A solution of EÇmf (416 mg, 0.832 mmol), TBDMSCl (376 mg, 2.50 mmol) and 
imidazole (170 mg, 2.50 mmol) in a mixture of  pyridine and DMF (1:1, 10 mL) was stirred at 
22 °C for 24 h. The reaction mixture was poured onto ice and extracted with EtOAc (3 x 100 
mL), the combined organic phases were dried over Na2SO4 and the solvent was removed in 
vacuo. The residue was purified by flash-column chromatography, using a gradient elution 
(100:0 to 90:10, CH2Cl2:MeOH), to yield TBDMS-EÇmf (600 mg, 99%) as a pale yellow solid. 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C38H65N4O6Si2+: 729.4437 [M+H]+; found 729.4436. 
3-((2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-
butyldimethylsilyl)oxy)methyl)-3-methoxytetrahydrofuran-2-yl)-7,7,9,9-tetraethyl-8-
oxyl-7,8,9,11-tetrahydropyrimido[4',5':5,6][1,4]oxazino[2,3-f]isoindol-2(3H)-one (10). To 
a solution of TBDMS-EÇmf (153 mg, 0.249 mmol) in CH2Cl2 (10 mL) was added NaN3 (65 mg, 
1.0 mmol) and the solution stirred at 22 °C for 15 min. m-CPBA (86 mg, 0.5 mmol) was added, 
the solution stirred for 30 h, the solvent removed in vacuo and the crude product purified by 
flash-column chromatography, using a gradient elution (100:0 to 83:17, CH2Cl2:MeOH), to yield 
10 (150 mg, 81%) as a bright yellow solid. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 





f]isoindol-2(3H)-one (EÇm). To a solution of EÇm (377 mg, 0.507 mmol) in THF (3 mL) was 
added TBAF (1.50 ml, 5.07 mmol) and the reaction mixture was stirred at 22 °C for 12 h. The 
solvent was removed in vacuo and the residue purified by flash-column chromatography, using 
a gradient elution (100:0 to 90:10, CH2Cl2:MeOH), to yield EÇm (249 mg, 94%) as a yellow 
solid. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C26H35N4O7Na•+: 538.2403; found 538.2399. 
3-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-3-
methoxytetrahydrofuran-2-yl)-7,7,9,9-tetraethyl-8-oxidanyl-7,8,9,11-
tetrahydropyrimido[4',5':5,6][1,4]oxazino[2,3-f]isoindol-2(3H)-one (EÇm-DMT). Residual 
MeOH was co-evaporated with toluene (3 x 5 mL) from EÇm (400 mg, 0.776 mmol), followed 
by sequential addition of pyridine (4 mL), DMTCl (315 mg, 0.930 mmol) and DMAP (18.6 mg, 
0.155 mmol). The solution was stirred at 22°C for 14 h, MeOH (400 μL) was added and the 
solvent removed in vacuo. The residue was purified by flash-column chromatography, using a 
gradient elution (99:1:0 to 98:1:1, CH2Cl2:Et3N:MeOH), to yield EÇm-DMT (514 mg, 81%) as 




f]isoindol-3(2H)-yl)tetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite 
(12). A solution of EÇm-DMT (225 mg, 0.275 mmol) in CH2Cl2 (1 mL) was treated with 
diisopropylammonium tetrazolide (70.6 mg, 0.413 mmol) and 2-cyanoethyl N,N,N´,N´-
tetraisopropylphosphorodiamidite (262 μL, 0.825 mmol). The solution was stirred at 22 °C for 
18 h. CH2Cl2 (25 mL) was added and the organic phase washed sequentially with satd. aq. 
NaHCO3 (3 × 30 mL) and brine (50 mL), dried with Na2SO4 and concentrated in vacuo. The 
residue was dissolved in a minimum amount of CH2Cl2 (few drops), followed by a slow addition 
of n-hexane (40-50 mL) at 22 °C. The solvent was decanted from the precipitate and discarded. 
This procedure was repeated six times to yield 12 (199 mg, 71%) as a yellow solid. 31P NMR 





2,7,9,11-tetrahydropyrimido[4',5':5,6][1,4]oxazino[2,3-f]isoindol-8(3H)-yl benzoate (13). 
To a solution of 10 (227 mg, 0.305 mmol) in 1,4-dioxane (30 mL) was added L-ascorbic acid 
(537 mg, 3.05 mmol) in H2O (5 mL). The solution was stirred at 60 °C for 24 h, after which 
CH2Cl2 (30 mL) and H2O (30 mL) were added and the mixture stirred vigorously for 2 min. The 
organic phase was filtered through a short column of Na2SO4 into a solution of BzCl (198 μL, 
1.53 mmol) and Et3N (220 μL, 1.53 mmol) in CH2Cl2 (10 mL). The solution was stirred at 22 °C 
for 2 h, washed with satd. aq. NaHCO3 (3 x 100 mL), the organic phase dried over Na2SO4 
and concentrated in vacuo. The residue purified by flash-column chromatography, using a 
gradient elution (100:0 to 90:10, CH2Cl2:MeOH), to yield 13 (259 mg, quant.) as a yellow solid. 
1H NMR (400 MHz, CDCl3) δ = 8.18 – 8.12 (m, 1H), 8.12 – 8.05 (m, 2H), 7.84 (s, 1H), 7.62 – 
7.53 (m, 2H), 7.53 – 7.42 (m, 3H), 6.39 (s, 1H), 5.88 (d, J = 9.6 Hz, 1H), 4.29 – 4.20 (m, 1H), 
4.13 (dd, J = 12.1, 2.0 Hz, 1H), 4.05 (d, J = 8.9 Hz, 1H), 3.82 (dd, J = 11.9, 1.6 Hz, 1H), 3.65 
(s, 4H), 2.23 – 1.56 (m, 8H), 0.96 (d, J = 39.9 Hz, 30H), 0.21 (d, J = 7.0 Hz, 6H), 0.10 (d, J = 
5.2 Hz, 6H) ppm. 13C{1H} NMR (101 MHz, CDCl3) δ = 165.9, 155.3, 153.4, 142.0, 137.7, 137.4, 
133.3, 133.0, 130.2, 129.6, 128.5, 128.3, 127.6, 125.6, 122.0, 113.3, 110.1, 87.9, 84.1, 83.1, 
74.4, 74.2, 68.0, 60.5, 57.9, 30.2, 29.2, 26.3, 25.8, 18.7, 18.1, 9.5, 8.7, -4.5, -4.9, -5.2, -5.4 
ppm. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C45H68N4O8Si2Na+: 871.4473; found 871.4468 
7,7,9,9-tetraethyl-3-((2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-
methoxytetrahydrofuran-2-yl)-2-oxo-2,7,9,11-
tetrahydropyrimido[4',5':5,6][1,4]oxazino[2,3-f]isoindol-8(3H)-yl benzoate (Bz-EÇm). To 
a solution of compound 13 (250 mg, 0.294 mmol) in THF (10 mL) was added TBAF (0.863 mL, 
2.95 mmol, 1.0 M in THF) and the reaction was stirred at 22 °C for 12 h. The solvent was 
removed in vacuo and the residue purified by flash-column chromatography, using a gradient 
elution (100:0 to 90:10, CH2Cl2:MeOH), to yield Bz-EÇm (168 mg, 92%) as a yellow solid. 1H 
NMR (400 MHz, CDCl3) δ = 8.33 – 8.25 (m, 3H), 7.91 – 7.84 (m, 1H), 7.75 (t, J = 7.7 Hz, 2H), 
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6.83 (d, J = 19.3 Hz, 2H), 6.18 (d, J = 2.3 Hz, 1H), 4.51 (dd, J = 7.2, 5.0 Hz, 1H), 4.34 – 4.18 
(m, 2H), 4.07 (dd, J = 12.3, 2.3 Hz, 2H), 3.86 (s, 3H), 2.42 – 1.82 (m, 9H), 1.31 – 1.00 (m, 14H) 
ppm. 13C{1H} NMR (101 MHz, CDCl3) δ = 166.1, 153.2, 141.9, 138.6, 137.0, 133.0, 129.1, 
128.8, 128.3, 128.1, 124.2, 123.0, 111.6, 110.8, 88.1, 84.1, 83.8, 77.4, 74.0, 73.9, 67.5, 59.5, 
57.8, 48.7, 48.5, 48.3, 48.1, 47.9, 47.7, 47.5, 29.9, 29.2, 28.7, 8.7, 7.9 ppm. HRMS (ESI-TOF) 




DMT). Residual MeOH was co-evaporated with toluene (3 x 5 mL) from Bz-EÇm (118 mg, 
0.192 mmol), followed by sequential addition of pyridine (4 mL), DMTCl (192 mg, 0.572 mmol) 
and DMAP (12.0 mg, 0.0952 mmol). The solution was stirred at 22°C for 14 h, MeOH (400 μL) 
was added and the solvent removed in vacuo. The residue was purified by flash-column 
chromatography, using a gradient elution (99:1:0 to 98:1:1, CH2Cl2:Et3N:MeOH), to yield Bz-
EÇm-DMT (151 mg, 86%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ = 8.02 – 7.96 (m, 
2H), 7.57 – 7.46 (m, 2H), 7.46 – 7.35 (m, 5H), 7.35 – 7.27 (m, 5H), 7.27 – 7.16 (m, 3H), 7.10 
(t, J = 7.3 Hz, 2H), 6.82 – 6.73 (m, 5H), 6.08 (d, J = 18.3 Hz, 1H), 5.82 (s, 1H), 4.35 (s, 1H), 
4.01 – 3.88 (m, 1H), 3.76 (d, J = 5.3 Hz, 1H), 3.67 (s, 7H), 3.62 (s, 3H), 3.45 (s, 3H), 1.98 – 
1.58 (m, 9H), 0.95 – 0.78 (m, 13H) ppm. 13C{1H} NMR (101 MHz, CDCl3) δ = 166.0, 158.6, 
158.5, 155.2, 153.8, 145.1, 141.7, 137.2, 135.3, 133.0, 130.4, 130.1, 129.6, 129.5, 128.5, 
127.95, 127.92, 126.7, 125.3, 121.4, 113.3, 113.2, 110.3, 87.8, 86.7, 83.8, 82.7, 74.3, 74.2, 
68.5, 58.4, 55.2, 46.0, 30.2, 29.7, 29.2, 9.4, 9.1, 8.7 ppm. HRMS (ESI-TOF) m/z: [M + Na]+ 




f]isoindol-8(3H)-yl benzoate (14). A solution of Bz-EÇm-DMT (150 mg, 0.163 mmol) in 
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CH2Cl2 (3 mL) was treated with diisopropylammonium tetrazolide (41.8 mg, 0.244 mmol) and 
2-cyanoethyl N,N,N´,N´-tetraisopropylphosphorodiamidite (155 μL, 0.488 mmol). The solution 
was stirred at 22 °C for 18 h. CH2Cl2 (25 mL) was added and the organic phase washed 
sequentially with satd. aq. NaHCO3 (3 × 30 mL) and brine (50 mL), dried over Na2SO4 and 
concentrated in vacuo. The residue was dissolved in a minimum amount of CH2Cl2 (few drops), 
followed by a slow addition of n-hexane (40-50 mL) at 22 °C. The solvent was decanted from 
the precipitate and discarded. This procedure was repeated six times to yield 14 (130 mg, 
71%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ = 8.12 – 8.03 (m, 4H), 7.68 (d, J = 19.9 
Hz, 2H), 7.62 – 7.54 (m, 3H), 7.54 – 7.44 (m, 9H), 7.44 – 7.34 (m, 9H), 7.30 (td, J = 7.8, 2.4 
Hz, 5H), 7.20 (t, J = 7.3 Hz, 2H), 6.86 (dtd, J = 8.8, 6.7, 6.2, 3.4 Hz, 8H), 6.23 – 5.87 (m, 4H), 
4.57 (d, J = 15.0 Hz, 1H), 4.34 (d, J = 12.8 Hz, 1H), 4.24 (d, J = 7.8 Hz, 2H), 3.90 (ddd, J = 
19.9, 10.0, 5.4 Hz, 3H), 3.81 (d, J = 2.2 Hz, 1H), 3.77 (d, J = 2.3 Hz, 12H), 3.63 (d, J = 2.6 Hz, 
8H), 3.61 – 3.53 (m, 5H), 3.52 – 3.41 (m, 4H), 2.63 (t, J = 6.1 Hz, 2H), 2.42 (t, J = 6.4 Hz, 2H), 
2.16 – 1.50 (m, 23H), 1.17 (dd, J = 15.1, 6.8 Hz, 19H), 1.04 (d, J = 6.7 Hz, 7H) ppm. 13C{1H} 
NMR (101 MHz, CDCl3) δ = 158.7, 158.6, 133.0, 130.5, 130.3, 129.6, 128.5, 128.1, 127.9, 
113.2, 110.3, 77.2, 74.3, 74.2, 58.0, 55.3, 55.2, 43.4, 43.2, 31.6, 24.7, 24.7, 24.6, 24.5, 22.7, 
20.3, 14.1, 9.4, 8.7 ppm. 31P NMR (162 MHz, CDCl3) δ = 150.84, 150.02. HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C63H75N6O11PNa+: 1145.5129; found 1145.5098. 
DNA and RNA synthesis and purification. Unmodified phosphoramidites (2’-deoxy for DNA 
and 2’O-TBDMS protected for RNA) were dissolved in CH3CN (0.1 M) and phosphoramidites 
11, 12 and 14 were dissolved in 1,2-dichloroethane (0.1 M). 5-Ethylthiotetrazole (0.25 M in 
CH3CN) was used as a coupling agent for DNA and 5-benzylthiotetrazole (0.25 M in CH3CN) 
for RNA. The coupling time was set to 1.5 min for unmodified phosphoramidites of DNA, 5 min 
for the EÇ-modified phosphoramidite 11 and 7 min for both unmodified phosphoramidites of 
RNA and EÇm-modified phosphoramidites 12 and 14. After completion of the DNA synthesis, 
the DNAs were cleaved from the resin and deprotected in a sat. aq. NH3 solution at 55 °C for 
8 h, after which the solvent was removed in vacuo. After completion of the RNA synthesis, the 
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RNAs synthesized using phosphoramidite 12 were deprotected and cleaved from the resin in 
a 1:1 solution (2 mL) of CH3NH2 (8 M in EtOH) and NH3 (33% w/w in H2O) at 65 °C for 1 h, 
while the oligonucleotides synthesized using phosphoramidite 14 were deprotected and 
cleaved from the resin in a 1:1 solution (2 mL) of CH3NH2 (40% in H2O) and NH3 (40% w/w in 
H2O) at 65 °C for 2.5 h. The solvent was removed in vacuo and the 2’O-TBDMS groups were 
removed by incubation in a solution of Et3N·3HF (300 μL) in DMF (100 μL) at 55 °C for 1.5 h, 
followed by addition of deionized and sterilized water (100 μL). This solution was transferred 
to a 50 mL Falcon tube, n-butanol (20 mL) was added and the mixture stored at −20 °C for 14 
h, centrifuged at 4°C and the solvent decanted from the RNA pellet.  
All oligonucleotides were subsequently purified by 20% DPAGE and extracted from the gel 
slices using the “crush and soak method” with Tris buffer (250 mM NaCl, 10 mM Tris, 1 mM 
Na2EDTA, pH 7.5). The solutions were filtered through GD/X syringe filters (0.45 μm, 25 mm 
diameter, Whatman, USA) and subsequently desalted using Sep-Pak cartridges (Waters, 
USA), following the instructions provided by the manufacturer. Dried oligonucleotides were 
dissolved in deionized and sterilized water (200 μL for each oligonucleotide).  
Enzymatic digestion of DNA and RNA and HPLC analysis. To the oligonucleotide (4 nmol) 
in sterile water (8 μL) was added calf intestinal alkaline phosphatase (1 μL, 2 U), snake venom 
phosphodiesterase I (4 μL, 0.2 U), nuclease P1 from penicillium citrinum (5 μL, 1.5 U) and Tris 
buffer (2 μL, 0.5 M Tris and 0.1 M MgCl2). The samples were incubated at 37 °C for 50 h, after 
which they were analyzed by HPLC chromatography (Figure S30 and Figure S31). 
CD measurements. To determine if EÇ and EÇm labels had any effect on the DNA and RNA 
duplex conformation, circular dichroism (CD) spectra of all unmodified duplexes and their spin-
labeled counterparts were recorded. DNA and RNA duplexes were prepared by dissolving 
complimentary single-stranded oligonucleotides (2.5 nmol) of each in a phosphate buffer (100 
μL; 10 mM phosphate, 100 mM NaCl, 0.1 mM Na2EDTA, pH 7.0) and annealed. The annealed 
samples were diluted to 200 μL with the same buffer (Figure S32).  
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Thermal denaturing experiments. To determine if EÇ or EÇm affected the stability of the 
DNA or RNA duplexes, the thermal denaturation curves of unmodified and spin-labeled 
oligomers were determined. Both DNA and RNA samples were prepared by dissolving 4.0 
nmol of each strand in a phosphate buffer (100 μL; 10 mM phosphate, 100 mM NaCl, 0.1 mM 
Na2EDTA, pH 7.0), annealed, diluted to 1.0 mL with the phosphate buffer (pH 7.0) and 
degassed with Ar. The samples were heated up from 22 °C to 90 °C (1.0 °C/min) and the 
absorbance at 260 nm was recorded at 1.0 °C intervals (Table 1, Figure S33).  
CW-EPR measurements and spin counting. Samples of spin-labeled oligonucleotides for 
EPR measurements were prepared by dissolving spin-labeled, single stranded DNA or RNA 
(2.0 nmol) in phosphate buffer (10 μL; 10 mM phosphate, 100 mM NaCl, 0.1 mM Na2EDTA, 
pH 7.0, oligonucleotide final conc. 200 μM) (Figure S34). The amount of spin labels in each 
oligonucleotide was determined by spin counting. A stock solution of 4-hydroxy-TEMPO (1.0 
M) was prepared in phosphate buffer (10 mM phosphate, 100 mM NaCl, 0.1 mM Na2EDTA, 
pH 7.0). The stock solution was diluted into samples of different concentrations (0-0.5 mM) 
and each sample was measured by EPR spectroscopy. The area under the peaks of each 
spectrum, obtained by double integration, was plotted against its concentration to yield a 
standard curve, used to determine the spin-labeling efficiency with an error margin of 5-10% 
(Table S1). 
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